Lukas Scheibler | Executive Vice President of Research and Development
Acucela

Lukas Scheibler, Executive Vice President of Research and Development, Acucela

Dr. Scheibler joined Acucela in August 2015 after a 13-year career in research and development, business development and clinical trial management at Novartis. Dr. Scheibler had worked since 2008 at Alcon, a division of Novartis. He most recently was a Vice President in charge of Alcon's Ideation and Technology Evaluation Center, the company's center of excellence in charge of identifying novel technologies that address unmet needs in ophthalmology. Before that, he served as Alcon's Vice President and Global Head of Clinical Trial Management. Dr. Scheibler started work at Novartis headquarters in Switzerland in 2002 as Manager of Global Drug Regulatory Affairs. While he served as VP and Global Head of R&D Alliances at Alcon from 2008 to 2011, the company made several major acquisitions and deals, including the purchase of LenSx Lasers for up to US $744 million, ESBATech for up to US $589 million and a Research Agreement with AstraZeneca for exclusive access to the company's ophthalmology compound library. Dr. Scheibler received a Master's degree in chemistry from University of Basel, Switzerland; a Ph.D. in chemistry from University of Lausanne, Switzerland; and his Postdoctoral Training from Harvard Medical School.

back to speakers